News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for February 2025 Shelley Wood February 28, 2025
News Daily News Even on Tafamidis, ATTR-CM Patients Face High Mortality Over Time Michael O'Riordan February 13, 2025
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Daily News Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B Michael O'Riordan June 24, 2024
Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024
News Conference News ESC 2023 More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM Michael O'Riordan August 31, 2023
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020